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Abstract: Flash vacuum pyrolysis (FVP) at 500–600 °C of 1-sub-
stituted pyrazolylaminomethylene derivatives of Meldrum’s acid
provides 1-substituted pyrazolo[3,4-b]pyridin-4-ones in high
yields. If the 1-substituent is a tert-butyl group, FVP at 750–850 °C
causes elimination of 2-methyl-1-propene to give the parent pyrazo-
lo[3,4-b]pyridin-4-one.
Key words: gas-phase reactions, pericyclic reactions, heterocycles,
Meldrum’s acid, medicinal chemistry
There are very few references to 1-unsubstituted pyrazo-
lo[3,4-b]pyridin-4-ones 1 in the literature2 and all known
derivatives except the parent compound 1 (R = R′ = H)
have a substituent in the 6-position. Potential functional-
ization of the 4-position (e.g., via the triflate or the 4-
chloro compound) would provide 4-substituted pyrazo-
lo[3,4-b]pyridines 2 (Figure 1), which have shown diverse
application in medicinal chemistry.3 On the other hand,
substitution at the 1-position generally results in loss of
biological activity due to the disruption of the hydrogen
bonding regime.4 
Figure 1  1-Unsubstituted pyrazolo[3,4-b]pyridin-4-ones 1 and 4-
substituted pyrazolo[3,4-b]pyridines 2
In earlier work, we explored a potential route to 1 by flash
vacuum pyrolysis (FVP) of Meldrum’s acid derivatives
[e.g., 3 (R1 = H)], but cyclization of the imidoylketene in-
termediate 4 (R1 = H) occurred exclusively at the adjacent
nitrogen atom to provide a useful route to the pyrazo-
lo[1,5-a]pyrimidine system 5 (Scheme 1).5 Clearly this
route must be blocked to provide pyrazolo[3,4-b]pyridin-
4-ones.
The present work therefore had a range of objectives.
First, 3 (R1 = alkyl or aryl) were synthesized and pyro-
lyzed to ensure that, in the absence of the pyrazole NH,
cyclization onto the adjacent carbon atom to give 1 (R =
1-alkyl or 1-aryl) would take place (Scheme 1), as ob-
served in many related systems.6 Second, we explored the
design of a thermal N-protecting group, which would re-
main at low furnace temperatures, but be selectively re-
moved at higher furnace temperatures to provide N-
unsubstituted pyrazolopyridinones 1 (R1 = H). If the pre-
vious stages were successful, we aimed finally to func-
tionalize the 4-position of the pyrazolo[3,4-b]pyridin-4-
ones to establish that the route has significant potential for
the synthesis of pyrazolo[3,4-b]pyridines 2.
The 1-substituted and 1,3-disubstituted 3-aminopyrazoles
6a–f (Figure 2) were either commercially available or
were synthesized by known methods. Compounds 6c,7
6e,8 and 6f9a are known only in patents or are formed in
poor yield;9b their full characterization data are given here.
Compound 6c was formed as a 5:1 mixture of 6c and its
1-tert-butyl-3-amino isomer, which was taken on to the
next stage without purification. Reaction of 6a–f with
methoxymethylene Meldrum’s acid in acetonitrile gave
the aminomethylene derivatives 3a–f (Figure 2) in 89–
99% yield and (generally) high purity. Compound 3c was
purified by recrystallization before pyrolysis.
FVP of 3a and 3b at 600 °C (0.03 Torr) gave 1-methylpyr-
azolo[3,4-b]pyridin-4-one (1aa) (92%) and its 3-methyl-
1-phenyl analogue 1ba (95%), respectively, as involatile
solids that crystallized at the exit point of the furnace. It is
clear, therefore, that blocking the 1-position of the
pyrazole has the effect of diverting the cyclization to the
adjacent carbon atom to provide the target pyrazolopyrid-
inones.
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In order to access the 1-unsubstituted pyrazolo[3,4-b]pyr-
idines 1 (R1 = H), a thermally removable N-protecting
group was required. If a retro-ene reaction is possible, an
N-tert-butyl group is ideal because the only co-product is
2-methyl-1-propene. We have exploited this in the pyri-
dazin-3-one series10 and it is also known that N-tert-bu-
tylpyrazole (7) loses 2-methyl-1-propene at high
temperatures (Scheme 2).11 A temperature profile of this
reaction (Figure 3) shows that, in our apparatus, at tem-
peratures below 600 °C the N-alkyl product 7 is formed
exclusively whereas at temperatures above 850 °C, only
the deprotected product 8 was formed. It was therefore an-
ticipated that FVP of 3c–f in the range 500–600 °C should
provide the N-tert-butyl products 1 (R1 = t-Bu) whereas
FVP in the range 750–850 °C should provide the depro-
tected products 1 (R1 = H).
Scheme 2
Figure 3  Temperature-conversion plot for FVP of 7 
These predictions were borne out in practice. FVP of 3c–f
at 500 °C gave the pyrazolopyridinones 1ca, 1da, 1ea,
and 1fa (Figure 4) in 83–97% yields and at 750–850 °C
gave the deprotected products 1cb and 1db in 67–82%
yields whilst the more highly substituted derivatives 1eb
and 1fb were obtained as more complex mixtures.12 N-
Unsubstituted pyrazolopyridinones show exceptionally
broad peaks in their NMR spectra due to tautomerization,
but the two NH resonances at ca. δH = 12.8–13.8 and
11.5–11.8 are characteristic, as previously reported.2a
Figure 4  Pyrazolopyridinones 1
As an alternative to the one-pass cyclization-deprotection
described above, the protecting group can be retained pri-
or to functionalization of the 4-oxo substituent. This strat-
egy is illustrated for the 3-phenyl series 1e, which was
chosen as it might prove unreactive owing to peri interac-
tions with the 3-substituent.
Thus, treatment of 1ea with phosphoryl chloride gave the
4-chloro compound 9 (99%), which could either be ther-
mally deprotected to 10 (87%), or reacted further. For ex-
ample, reaction of 9 with pyrrolidine in the absence of a
catalyst provided a low yield of the pyrrolidino compound
11 (37%); alternatively, reaction with aniline under
Buchwald–Hartwig conditions gave the anilino com-
pound 12 (87%), which could be thermally deprotected to
13 (72%) (Scheme 3).
Scheme 3
In conclusion, the work described here has provided a
flexible gas-phase route to pyrazolo[3,4-b]pyridin-4-ones
Figure 2  1,3-Disubstituted 3-aminopyrazoles 6 and aminometh-
ylene derivatives 3
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and pyrazolo[3,4-b]pyridines. An important feature of the
strategy is the use of an N-tert-butyl group, which may be
retained at low furnace temperatures (allowing function-
alization of the 4-oxo group) or removed at high furnace
temperatures to provide a one-pass route to N-unsubstitut-
ed analogues.
1H and 13C NMR spectra were recorded at 500 or 250 MHz and 125
or 63 MHz, respectively, unless otherwise stated. Chemical shifts
are given in ppm relative to TMS. Mass spectra were recorded under
electron impact conditions.
5-Amino-1-tert-butyl-1H-pyrazole (6c)7
tert-Butylhydrazine hydrochloride (5.99 g, 48.1 mmol) was added
to EtOH (60 mL) to form a slurry. To this was added NaOAc (7.93
g, 96.7 mmol) and 2-chloroacrylonitrile (5 mL, 62.6 mmol). The
solution was heated to 80 °C for 18 h, cooled, and the solvent re-
moved in vacuo. The residue was slowly diluted with distilled H2O
(35 mL) and partitioned between sat. aq NaHCO3 (40 mL) and
EtOAc (40 mL). The organic layer was separated and the aqueous
layer was extracted with EtOAc (2 × 20 mL). The organic layers
were combined, washed with brine (20 mL), dried (MgSO4), and the
solvent removed in vacuo to afford a red oil; yield: 7.95 g (91%); bp
93–94 °C/0.9 Torr (yellow liquid). The product was a 5:1 mixture
of the title compound 6c and its 1-tert-butyl-3-amino isomer. The
crude product was used to prepare the Meldrum’s acid derivative
3c, which was purified by recrystallization (see below). 
1H NMR (CDCl3): δ = 7.21 (d, 3J = 1.8 Hz, 1 H), 5.57 (d, 3J = 1.8
Hz, 1 H), 3.60 (br s, 2 H), 1.65 (s, 9 H). 
13C NMR (CDCl3): δ = 144.5 (Cq), 136.6 (CH), 94.1 (CH), 58.5
(Cq), 29.3 (3 CH3).
MS: m/z (%) = 139 (M+, 45), 83 (M – C4H10, 100). 
HRMS: m/z calcd for C7H13N3 (M+): 139.1104; found: 139.1103.
5-Amino-1-tert-butyl-3-phenyl-1H-pyrazole (6e)8
A solution of 3-oxo-3-phenylpropanenitrile (1.5 g, 10.3 mmol) in
EtOH (10 mL) was added to a slurry of tert-butylhydrazine hydro-
chloride (2.6 g, 20.7 mmol) in EtOH (35 mL) and the solution was
heated to reflux with stirring for 18 h. The solution was cooled, con-
centrated and the residue was partitioned between sat. aq NaHCO3
(30 mL) and EtOAc (30 mL). The organic layer was separated and
the aqueous layer was extracted with EtOAc (2 × 20 mL). The or-
ganic layers were combined, washed with brine (20 mL), dried
(MgSO4), and the solvent removed in vacuo to give 6e as a pale yel-
low solid; yield: 2.2 g (97%); mp 100–102 °C.
1H NMR (DMSO-d6): δ = 7.64 (d, 3J = 7.4 Hz, 2 H), 7.33 (t, 3J = 7.4
Hz, 2 H), 7.22 (t, 3J = 7.4 Hz, 1 H), 5.79 (s, 1 H), 4.97 (s, 2 H), 1.58
(s, 9 H). 
13C NMR (DMSO-d6): δ = 148.1 (Cq), 146.1 (Cq), 135.0 (Cq), 128.8
(2 CH), 127.1 (CH), 125.0 (2 CH) 89.2 (CH), 58.3 (Cq), 40.1 (3
CH3). 
MS: m/z (%) = 215 (M+, 25), 159 (100). 
HRMS: m/z calcd for C13H17N3 (M+): 215.1417; found: 215.1416.
5-Amino-1,3-di-tert-butyl-1H-pyrazole (6f)9
A solution of 4,4-dimethyl-3-oxovaleronitrile (1.75 g, 14.0 mmol)
in EtOH (10 mL) was added to a slurry of tert-butylhydrazine hy-
drochloride (3.5 g. 28.1 mmol) in EtOH (35 mL) and the solution
was heated to reflux with stirring for 18 h. The solution was cooled,
concentrated, and the residue was partitioned between sat. aq
NaHCO3 (30 mL) and EtOAc (30 mL). The organic layer was sep-
arated and the aqueous layer was extracted with EtOAc (2 × 20 mL).
The organic layers were combined, washed with brine (20 mL),
dried (MgSO4), and the solvent removed to give 6f as a pale orange
solid; yield: 1.8 g (66%); mp 67–69 °C (Lit.9a mp 64–66 °C). 
1H NMR (CDCl3): δ = 5.48 (s, 1 H), 3.46 (s, 2 H), 1.27 (s, 18 H). 
13C NMR (CDCl3): δ = 157.8 (Cq), 144.1 (Cq), 90.2 (CH), 58.2 (Cq),
44.7 (Cq), 30.4 (3 CH3), 29.5 (3 CH3). 
Spectra differ significantly from those reported,9b but were recorded
in a different solvent.
MS: m/z (%) = 195 (M+, 29), 139 (63), 124 (100). 
HRMS: m/z calcd for C11H21N3 (M+): 195.1730; found: 175.1728.
Meldrum’s Acid Derivatives; General Procedure
5-(Methoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (0.5 g,
2.9 mmol) was added to a stirred solution of the 5-aminopyrazole 6
(2.9 mmol) in MeCN (10 mL). After stirring for 1 h, the solvent was
removed in vacuo to complete the precipitation of the product.
5-(1-Methyl-1H-pyrazol-5-ylaminomethylene)-2,2-dimethyl-
1,3-dioxane-4,6-dione (3a) 
Treatment of 6a using the general procedure gave 3a; yield: 0.71 g
(98%); yellow solid; mp 144 °C (MeOH). 
1H NMR (CDCl3): δ = 11.28 (d, 3J = 13.3 Hz, 1 H), 8.34 (d, 3J = 13.3
Hz, 1 H), 7.34 (d, 3J = 2.1 Hz, 1 H), 6.18 (d, 3J = 2.1 Hz, 1 H), 3.85
(s, 3 H), 1.75 (s, 6 H). 
13C NMR (CDCl3): δ = 165.7 (Cq), 162.6 (Cq), 154.7 (CH), 139.1
(CH), 138.0 (Cq), 105.6 (Cq), 95.3 (CH), 88.9 (Cq), 35.4 (CH3), 27.1
(2 CH3).
MS: m/z (%) = 251 (M+, 16), 193 (100), 149 (14), 122 (40). 
Anal. Calcd for C11H13N3O4: C, 52.6; H, 5.2; N, 16.75. Found: C,
52.65; H, 5.35; N, 16.8. 
5-(3-Methyl-1-phenyl-1H-pyrazol-5-ylaminomethylene)-2,2-di-
methyl-1,3-dioxane-4,6-dione (3b) 
Treatment of 6b using the general procedure gave 3b; yield: 0.90 g
(95%); yellow solid; mp 167 °C (MeOH). 
1H NMR (CDCl3): δ = 11.45 (d, 3J = 13.4 Hz, 1 H), 8.38 (d, 3J = 13.4
Hz, 1 H), 7.56–7.42 (m, 5 H), 6.17 (s, 1 H), 2.34 (s, 3 H), 1.71 (s, 6
H). 
13C NMR (CDCl3): δ = 165.3 (Cq), 162.7 (Cq), 153.1 (CH), 150.1
(Cq), 138.3 (Cq), 136.8 (Cq), 130.0 (2 CH), 128.8 (CH), 124.8 (2
CH), 105.5 (Cq), 94.3 (CH), 88.8 (Cq), 27.1 (2 CH3), 14.0 (CH3).
MS: m/z (%) = 327 (M+, 23), 269 (100), 225 (22), 184 (74), 156
(22). 
Anal. Calcd for C17H17N3O4: C, 62.4; H, 5.25; N, 12.85. Found: C,
62.3; H, 5.15; N, 12.75. 
5-(1-tert-Butyl-1H-pyrazol-5-ylamino)methylene-2,2-dimethyl-
1,3-dioxane-5,6-dione (3c)
Treatment of 6c using the general procedure gave 3c; yield: 0.985 g
(97%); yellow solid; mp 84 °C. 
1H NMR (CDCl3): δ = 11.53 (d, 3J = 13.4 Hz, 1 H), 8.33 (d, 3J = 13.4
Hz, 1 H), 7.41 (d, 3J = 1.9 Hz, 1 H), 6.23 (d, 3J = 1.9 Hz, 1 H), 1.77
(s, 6 H), 1.70 (s, 9 H). 
13C NMR (CDCl3): δ = 165.6 (Cq), 162.9 (Cq), 154.7 (CH), 137.5
(Cq), 137.3 (CH), 105.6 (Cq), 97.8 (CH), 88.4 (Cq), 60.3 (Cq), 29.8
(3 CH3), 27.3 (2 CH3).
MS: m/z (%) = 293 (M+, 21), 235 (47), 179 (59), 161 (100). 
HRMS: m/z calcd for C14H19N3O4 (M+): 293.1381; found:
293.1384.
5-(1-tert-Butyl-3-methyl-1H-pyrazol-5-ylamine)-2,2-dimethyl-
1,3-dioxane-4,6-dione (3d) 
Treatment of 6d using the general procedure gave 3d; yield: 0.88 g
(99%); yellow solid; mp 82 °C. 
1H NMR (CDCl3): δ = 11.47 (br d, 3J = 13.4 Hz, 1 H), 8.29 (d, 3J =
13.4 Hz, 1 H), 6.00 (s, 1 H), 2.23 (s, 3 H), 1.75 (s, 6 H), 1.66 (s, 9 H). 
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13C NMR (CDCl3): δ = 165.9 (Cq), 162.9 (Cq), 154.4 (CH), 146.2
(Cq), 137.7 (Cq), 105.5 (Cq), 97.1 (CH), 88.1 (Cq), 59.7 (Cq), 29.8 (3
CH3), 27.1 (2 CH3), 13.9 (CH3).
MS: m/z (%) = 307 (M+, 21), 249 (100), 175 (68). 
HRMS: m/z calcd for C15H21N3O4 (M+): 307.1527; found:
307.1533.
5-(1-tert-Butyl-3-phenyl-1H-pyrazol-5-ylamino)methylene-2,2-
dimethyl-1,3-dioxane-4,6-dione (3e)
Treatment of 6e using the general procedure gave 3e; yield: 0.97 g
(98%); yellow solid; mp 152 °C. 
1H NMR (CDCl3): δ = 11.59 (d, 3J = 13.4 Hz, 1 H), 8.43 (d, 3J = 13.4
Hz, 1 H), 7.80 (d, 3J = 7.3 Hz, 2 H), 7.44 (t, 3J = 7.3 Hz, 2 H), 7.35
(t, 3J = 7.3 Hz, 1 H), 6.75 (s, 1 H), 1.81 (s, 6 H), 1.77 (s, 9 H). 
13C NMR (CDCl3): δ = 166.0 (Cq), 162.9 (Cq), 154.4 (CH), 148.5
(Cq), 138.8 (Cq), 132.8 (Cq), 128.7 (2 CH), 128.1 (CH), 125.3 (2
CH), 105.7 (Cq), 94.5 (CH), 88.5 (Cq), 60.6 (Cq), 29.9 (3 CH3), 27.2
(2 CH3).
MS: m/z (%) = 369 (M+, 33), 311 (100), 237 (58), 211 (57), 183
(44), 108 (45). 
HRMS: m/z calcd for C20H23N3O4 (M+): 369.1683; found:
369.1690.
5-(1,3-Di-tert-butyl-1H-pyrazol-5-ylamino)methylene-2,2-di-
methyl-1,3-dioxane-5,6-dione (3f)
Treatment of 6f using the general procedure gave 3f, yield: 0.83 g
(89%); yellow solid; mp 105 °C. 
1H NMR (CDCl3): δ = 11.47 (d, 3J = 13.1 Hz, 1 H), 8.35 (d, 3J = 13.1
Hz, 1 H), 6.08 (s, 1 H), 1.78 (s, 6 H), 1.67 (s, 9 H), 1.28 (s, 9 H). 
13C NMR (CDCl3): δ = 165.9 (Cq), 163.1 (Cq), 158.9 (Cq), 154.6
(CH), 137.0 (Cq), 105.5 (Cq), 94.0 (CH), 87.8 (Cq), 59.8 (Cq), 32.3
(Cq), 30.3 (3 CH3), 29.9 (3 CH3), 27.1 (2 CH3).
MS: m/z (%) = 349 (M+, 24), 291 (100), 217 (27), 202 (45), 176
(56). 
HRMS: m/z calcd for C18H27N3O4 (M+): 349.1996; found:
349.2000.
FVP Reactions
Flash vacuum pyrolysis reactions were carried out by distillation of
the substrate in vacuo through an electrically heated silica furnace
tube (35 × 2.5 cm). Products were trapped in a U-tube situated at the
exit point of the furnace and cooled with liquid N2. Conditions were
first established on a small scale (20 mg) where the product(s) were
dissolved in a deuterated solvent and analyzed directly by 1H NMR
spectroscopy. Larger-scale pyrolyses, involving 0.1 g or more of
substrate, were usually removed from the trap by solution in CH2Cl2
(30 mL). The precursors and pyrolysis conditions [quantity of pre-
cursor, inlet temperature (Ti), furnace temperature (Tf), pressure
range (P), and pyrolysis time (t)] and yields are stated.
FVP of 1-tert-Butylpyrazole (7) 
This compound was too volatile for normal inlet conditions. It was
therefore cooled in an acetone-dry ice bath, which was slowly re-
moved to allow sublimation (20 mg, Ti acetone/dry ice bath, Tf 600–
850 °C, P 0.03 Torr, t 15 min). 
1-Methyl-1,7-dihydropyrazolo[3,4-b]pyridin-4-one (1aa) 
FVP of 3a (recrystallized from MeOH, 203 mg, 0.81 mmol, Ti
199 °C, Tf 600 °C, P 0.03 Torr, t 30 min) gave 1aa; yield: 111 mg
(92%); off-white solid; mp 164 °C (Lit.13 mp 165–168 °C).
1H NMR (DMSO-d6): δ = 8.37 (d, 3J = 4.0 Hz, 1 H), 8.30 (s, 1 H),
6.65 (br s, 1 H), 4.22 (s, 3 H). 
13C NMR (DMSO-d6): δ = 162.4 (br Cq), 150.7 (br Cq), 148.1 (br
CH), 130.6 (CH), 107.9 (br Cq), 104.4 (CH), 33.9 (CH3).
MS: m/z (%) = 149 (M+, 100), 95 (12), 78 (14), 63 (13). 
HRMS: m/z calcd for C7H7N3O (M+): 149.0584; found: 149.0584.
3-Methyl-1,7-dihydro-1-phenylpyrazolo[3,4-b]pyridin-4-one 
(1ba) 
FVP of 3b (recrystallized from MeOH, 195 mg, 0.60 mmol, Ti
170 °C, Tf 600 °C, P 0.03 Torr, t 45 min) gave 1ba; yield: 0.129 mg
(95%); off-white solid; mp 195 °C. 
1H NMR (DMSO-d6): δ = 11.76 (s, 1 H), 8.31 (br m, 3 H), 7.57 (app
t, 3J = 7.8 Hz, 2 H), 7.32 (d, 3J = 7.3 Hz, 1 H), 6.66 (br s, 1 H), 2.68
(s, 3 H). 
13C NMR (DMSO-d6): δ = 160.6 (Cq), 153.1 (Cq), 150.9 (CH), 142.0
(Cq), 139.5 (Cq), 128.9 (2 CH), 124.9 (CH), 119.7 (2 CH), 107.4
(Cq), 103.2 (CH), 14.3 (CH3).
MS: m/z (%) = 226 (M+, 30), 225 (100), 79 (15), 78 (39). 
HRMS: m/z calcd for C13H11N3O (M+): 225.0897; found: 225.0896.
1-tert-Butyl-1,7-dihydropyrazolo[3,4-b]pyridin-4-one (1ca) 
FVP of 3c (recrystallized from cyclohexane, 300 mg, 1.02 mmol, Ti
210 °C, Tf 500 °C, P 0.03 Torr, t 0.5 h) gave 1ca; yield: 185 mg
(95%); yellow solid; mp 189–191 °C. 
1H NMR (DMSO-d6): δ = 11.40 (s, 1 H), 8.12 (br s, 1 H), 8.02 (s, 1
H), 6.49 (br s, 1 H), 1.74 (s, 9 H). 13C NMR (DMSO-d6): δ = 159.3
(Cq), 152.9 (Cq), 149.7 (CH), 128.5 (CH), 108.9 (Cq), 102.2 (CH),
59.6 (Cq), 29.2 (3 CH3).
MS: m/z (%) = 191 (M+, 24), 135 (56).
HRMS: m/z calcd for C10H13N3O (M+): 191.1064; found: 191.1060.
1,7-Dihydropyrazolo[3,4-b]pyridin-4-one (1cb) 
FVP of 3c (recrystallized from cyclohexane, 50 mg, 0.17 mmol, Ti
210 °C, Tf 750 °C, P 0.03 Torr, t 0.5 h) was followed by distillation
of CH2Cl2 into the U-tube trap. The solvent was removed in vacuo
to afford a yellow solid, which was triturated with Et2O and filtered
under vacuum. The filtrate was further washed with Et2O to yield
1cb; yield: 24 mg (67%); pale brown solid; mp 327–330 °C (Lit.2d
mp 328–330 °C).
1H NMR (DMSO-d6): δ (major tautomer) = 13.54 (s, 1 H), 11.71 (s,
1 H), 8.28 (br s, 1 H), 7.62 (br s, 1 H), 5.66 (br s, 1 H). 
13C NMR (DMSO-d6): δ (major tautomer) = 177.1 (Cq), 151.2 (Cq),
139.2 (CH), 125.8 (CH), 113.4 (Cq), 107.3 (CH).
MS: m/z (%) = 135 (M+, 100). 
1-tert-Butyl-1,7-dihydro-3-methylpyrazolo[3,4-b]pyridin-4-one 
(1da) 
FVP of 3d (125 mg, 0.41 mmol, Ti 160 °C, Tf 500 °C, P 0.03 Torr,
t 1 h) gave 1da; yield: 0.70 g (83%); off-white solid; mp 158 °C. 
1H NMR (DMSO-d6): δ = 11.17 (br s, 1 H), 8.01 (d, 3J = 4.7 Hz, 1
H), 6.34 (d, 3J = 4.7 Hz, 1 H), 2.45 (s, 3 H), 1.63 (s, 9 H). 
13C NMR (DMSO-d6): δ = 160.7 (br Cq), 152.2 (br Cq), 147.5 (CH),
137.4 (br Cq), 107.2 (br Cq), 101.5 (CH), 58.5 (Cq), 28.8 (3 CH3),
14.3 (CH3).
MS: m/z (%) = 205 (M+, 48), 150, (22), 149 (100), 148 (26). 
HRMS: m/z calcd for C11H15N3O (M+): 205.1210; found: 205.1210.
3-Methyl-1,7-dihydropyrazolo[3,4-b]pyridin-3-one (1db) 
FVP of 3d (100 mg, 0.33 mmol, Ti 160 °C, Tf 850 °C, P 0.03 Torr,
t 45 min) gave 1db; yield: 0.40 g (82%); off-white solid; mp 254 °C. 
1H NMR (DMSO-d6): δ (major tautomer) = 13.11 (s, 1 H), 11.51 (s,
1 H), 7.50 (t, 3J = 6.3 Hz, 1 H), 5.55 (d, 3J = 6.3 Hz, 1 H), 2.53 (s, 3
H). 
13C NMR (DMSO-d6, 600 MHz): δ (major tautomer) = 178.1 (br
Cq), 151.5 (br Cq), 141.5 (br Cq), 138.6 (CH), 110.2 (Cq), 107.1
(CH), 11.0 (CH3).
MS: m/z (%) = 149 (M+, 80), 78 (100). 
HRMS: m/z calcd for C7H7N3O (M+): 149.0584; found: 149.0583.
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1-tert-Butyl-1,7-dihydro-3-phenylpyrazolo[3,4-b]pyridin-4-one 
(1ea) 
FVP of 3e (500 mg, 1.36 mmol, Ti 220 °C, Tf 500 °C, P 0.03 Torr,
t 0.5 h) gave 1ea; yield: 358 mg (96%); yellow solid; mp 295–
298 °C. 
1H NMR (CDCl3): δ = 11.51 (s, 1 H), 8.23 (d, 3J = 5.4 Hz, 1 H), 8.00
(d, 3J = 7.3 Hz, 2 H), 7.45 (t, 3J = 7.3 Hz, 2 H), 7.36 (t, 3J = 7.3 Hz,
1 H), 6.60 (d, 3J = 5.4 Hz, 1 H), 1.80 (s, 9 H). 
13C NMR (CDCl3): δ = 160.0 (Cq), 154.1 (Cq), 149.6 (CH), 140.7
(Cq), 134.1 (Cq), 129.0 (2 CH), 128.4 (2 CH), 128.0 (CH), 105.8
(Cq), 102.6 (CH), 59.9 (Cq), 29.2 (3 CH3).
MS: m/z (%) = 267 (M+, 33), 211 (100). 
HRMS: m/z calcd for C16H17N3O (M+): 267.1366; found: 267.1367.
1,7-Dihydro-3-phenylpyrazolo[3,4-b]pyridin-4-one (1eb) 
FVP of 3e (500 mg, 1.36 mmol, Ti 220 °C, Tf 750 °C, P 0.03 Torr,
t 0.5 h) was followed by distillation of CH2Cl2 into the U-tube trap.
The solution was removed and the insoluble product filtered under
vacuum to give 1eb; yield: 275 mg (96% mix12); off-white solid; mp
298 °C. 
1H NMR (DMSO-d6): δ (major tautomer) = 13.85 (br s, 1 H), 11.74
(br s, 1 H), 8.29 (br s, 1 H), 8.05 (br d, 3J = 4.9 Hz, 1 H), 7.63 (m, 2
H), 7.47 (m, 2 H), 5.71 (br s, 1 H).
MS: m/z (%) = 211 (M+, 34), 183 (100). 
HRMS: m/z calcd for C12H9N3O (M+): 211.0751; found: 211.0751.
1,3-Di-tert-butyl-1,7-dihydropyrazolo[3,4-b]pyridin-4-one (1fa)
FVP of 3f (500 mg, 1.43 mmol, Ti 200 °C, Tf 500 °C, P 0.03 Torr, t
0.5 h) was followed by distillation of CH2Cl2 into the U-tube trap.
The solution was removed and solvent removed in vacuo to afford
1fa; yield: 345 mg (97%); yellow solid; mp 264–266 °C. 
1H NMR (CDCl3): δ = 11.39 (s, 1 H), 8.13 (d, 3J = 4.7 Hz, 1 H), 6.50
(d, 3J = 4.7 Hz, 1 H), 1.71 (s, 9 H), 1.43 (s, 9 H). 
13C NMR (CDCl3): δ = 159.3 (Cq), 154.4 (Cq), 148.9 (CH), 139.4
(Cq), 105.7 (Cq), 101.9 (CH), 59.0 (Cq), 33.7 (Cq), 29.1 (3 CH3),
26.1 (3 CH3).
MS: m/z (%) = 247 (M+, 29), 232 (54), 232 (100). 
HRMS: m/z calcd for C14H21N3O (M+): 247.1685; found: 247.1690.
3-tert-Butyl-1,7-dihydropyrazolo[3,4-b]pyridin-4-one (1fb)
FVP of 3f (500 mg, 1.43 mmol, Ti 200 °C, Tf 750 °C, P 0.03 Torr, t
0.5 h) was followed by distillation of CH2Cl2 into the U-tube trap.
The solution was removed and the insoluble product 1fb was fil-
tered under vacuum; yield: 374 mg (95% mix12); off-white solid;
mp 265–266 °C. 
1H NMR (DMSO-d6): δ (major tautomer) = 12.88 (br s, 1 H), 11.56
(br s, 1 H), 7.59 (br s, 1 H), 5.63 (br s, 1 H), 1.44 (s, 9 H).
MS: m/z (%) = 191 (M+, 28), 176 (100), 149 (27). 
HRMS: m/z calcd for C10H13N3O (M+): 191.1059; found: 191.1063.
1-tert-Butyl-4-chloro-3-phenyl-1H-pyrazolo[3,4-b]pyridine (9)
Compound 1ea (1.00 g, 3.74 mmol) was dissolved in POCl3 (18
mL, 197 mmol) and heated to reflux for 4 h. The solution was
cooled, and the volume reduced in vacuo. H2O (40 mL) was added
slowly to the dark residue followed by sat. aq NaHCO3 (40 mL).
The aqueous layer was extracted with CH2Cl2 (3 × 30 mL), the com-
bined organic layers were washed with brine (30 mL), dried
(MgSO4), and the solvent removed in vacuo to afford 9; yield: 1.06
g (99%); brown solid; mp 123–125 °C. 
1H NMR (CDCl3): δ = 8.41 (d, 3J = 5.0 Hz, 1 H), 7.77 (m, 2 H), 7.48
(m, 3 H), 7.14 (d, 3J = 5.0 Hz, 1 H), 1.91 (s, 9 H). 
13C NMR (CDCl3): δ = 151.9 (Cq), 147.3 (CH), 141.6 (Cq), 137.7
(Cq), 133.1 (Cq), 130.5 (2 CH), 128.2 (CH), 127.9 (2 CH), 117.2
(CH), 113.5 (Cq), 60.7 (Cq), 29.2 (3 CH3).
MS: m/z (%) = 287 [M+ (37Cl), 10], 285 [M+ (35Cl), 31], 231 (32),
229 (100). 
HRMS: m/z calcd for C16H1635ClN3 (M+): 285.1038; found:
285.1039.
4-Chloro-3-phenyl-1H-pyrazolo[3,4-b]pyridine (10)
FVP of 9 (50 mg, 0.18 mmol, Ti 300 °C, Tf 750 °C, P 0.033 Torr, t
0.5 h) was followed by distillation of CH2Cl2 into the U-tube trap.
The solvent was removed in vacuo to afford 10; yield: 35 mg (87%);
pale brown solid; mp 274–277 °C. 
1H NMR (CDCl3): δ (major tautomer) = 12.85 (s, 1 H), 8.57 (d, 3J =
5.2 Hz, 1 H), 7.81 (d, 3J = 6.2 Hz, 2 H), 7.52 (m, 3 H), 7.26 (d, 3J =
5.2 Hz, 1 H). 
13C NMR (CDCl3): δ (major tautomer) = 153.7 (Cq), 149.1 (CH),
145.8 (Cq), 139.2 (Cq), 132.4 (Cq), 130.3 (2 CH), 128.7 (CH), 128.1
(2 CH), 118.3 (CH), 112.4 (Cq).
MS: m/z (%) = 231 [M+ (37Cl), 30], 229 [M+(35Cl), 100], 166 (50). 
HRMS: m/z calcd for C12H835ClN3 (M+): 229.0412; found:
229.0414.
1-tert-Butyl-3-phenyl-4-(pyrrolidin-1-yl)-1H-pyrazolo[3,4-
b]pyridine (11)
Pyrrolidine (1.0 mL, 11 mmol) was added to a solution of 9 (250
mg, 0.877 mmol) in 1,2-dimethoxyethane (15 mL) and the mixture
was heated at reflux with stirring for 18 h. The solvent was removed
and the residue was partitioned between sat. aq NaHCO3 (25 mL)
and EtOAc (25 mL). The organic layer was separated and the sol-
vent removed in vacuo to yield an orange residue, which was puri-
fied by dry flash chromatography eluting with hexane–EtOAc
(20:1). Product containing fractions were combined and solvent re-
moved in vacuo to give 11 as a yellow gum, which crystallized on
standing; yield: 87 mg (37%); mp 122–123 °C. 
1H NMR (CDCl3): δ = 8.18 (d, 3J = 5.5 Hz, 1 H), 7.66 (d, 3J = 6.9
Hz, 2 H), 7.42 (t, 3J = 7.6 Hz, 2 H), 7.35 (t, 3J = 8.6 Hz, 1 H), 6.28
(d, 3J = 5.5 Hz, 1 H), 3.06 (t, 3J = 6.5 Hz, 4 H), 1.89 (s, 9 H), 1.73
(t, 3J = 6.5 Hz, 4 H). 
13C NMR (CDCl3): δ = 153.3 (Cq), 151.5 (Cq), 147.4 (CH), 141.8
(Cq), 136.7 (Cq), 129.2 (2 CH), 128.4 (2 CH), 127.6 (CH), 106.0
(Cq), 99.6 (CH), 59.7 (Cq), 51.5 (2 CH2), 29.1 (3 CH3), 25.2 (2 CH2).
MS: m/z (%) = 320 (M+, 54), 264 (100), 263 (M – C3H6O, 38). 
HRMS: m/z calc for C20H24N4 (M+): 320.2007; found: 320.2005.
4-Anilino-1-tert-butyl-3-phenyl-1H-pyrazolo[3,4-b]pyridine 
(12)
A solution of 9 (285 mg, 1.00 mmol), aniline (0.1 mL, 1.1 mmol),
Pd2(dba)3 (18 mg, 0.02 mmol), dppp (16 mg, 0.04 mmol), and t-
BuONa (134 mg, 1.4 mmol) in toluene (10 mL) contained in an
oven-dried flask purged with N2, was heated to 70 °C for 72 h. The
mixture was cooled, taken up in Et2O (10 mL), washed with brine
(3 × 5 mL), and concentrated in vacuo to give the crude product,
which was purified by dry flash chromatography eluting with hex-
ane–EtOAc (20:1). Product containing fractions were combined
and solvent removed in vacuo to afford 12 as a yellow gum, which
crystallized on standing; yield: 280 mg (87%); mp 116–118 °C. 
1H NMR (CDCl3): δ = 8.23 (d, 3J = 5.5 Hz, 1 H), 7.68 (d, 3J = 6.9
Hz, 2 H), 7.77 (t, 3J = 7.5 Hz, 2 H), 7.55 (t, 3J = 7.4 Hz, 1 H), 7.38
(dd, 3J = 8.4, 7.4 Hz, 2 H)Hz,), 7.17 (m, 3 H), 6.72 (d, 3J = 5.5 Hz,
1 H), 6.62 (br s, 1 H), 1.91 (s, 9 H). 
13C NMR (CDCl3): δ = 152.8 (Cq), 148.8 (CH), 145.9 (Cq), 140.5
(Cq), 139.2 (Cq), 134.9 (Cq), 129.5 (2 CH), 129.3 (2 CH), 129.1 (2
CH), 128.6 (CH), 124.5 (CH), 122.3 (2 CH), 104.5 (Cq), 97.7 (CH),
60.0 (Cq), 29.2 (3 CH3).
MS: m/z (%) = 342 (M+, 42), 286 (100). 
HRMS: m/z calcd for C22H22N4 (M+): 342.1850; found: 342.1852.
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4-Anilino-3-phenyl-1H-pyrazolo[3,4-b]pyridine (13)
FVP of 12 (30 mg, 0.88 mmol, Ti 235 °C, Tf 750 °C, P 0.03 Torr, t
0.5 h) was followed by distillation of CH2Cl2 into the U-tube trap.
The solvent was removed in vacuo to afford 13; yield: 18 mg (72%);
pale yellow solid; mp 216–217 °C. 
1H NMR (CDCl3): δ (major tautomer) = 12.92 (br s, 1 H), 8.33 (d,3J = 5.7 Hz, 1 H), 7.81 (d, 3J = 7.3 Hz, 2 H), 7.58 (t, 3J = 7.4 Hz, 2
H), 7.52 (t, 3J = 7.4 Hz, 1 H), 7.41 (t, 3J = 7.9 Hz, 2 H), 7.23 (m, 3
H), 6.76 (d, 3J = 5.7 Hz, 1 H), 6.74 (s, 1 H). 
13C NMR (CDCl3): δ (major tautomer) = 154.7 (Cq), 150.3 (Cq),
146.8 (CH), 144.5 (Cq) 138.7 (Cq), 134.4 (Cq), 129.6 (2 CH), 129.3
(2 CH), 129.0 (2 CH), 128.9 (CH), 125.1 (CH), 122.8 (2 CH), 102.8
(Cq), 98.3 (CH).
MS: m/z (%) = 286 (M+, 100), 285 (58), 258 (58). 
HRMS: m/z calcd for C18H14N4 (M+): 286.1224; found: 286.1218.
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